Table 1

Data collection items and activities by visit during the study period for lowering-hyperuricaemia treatment on cardiovascular outcomes in peritoneal dialysis

	Screening period visit 1 −3 weeks to day 0		Visit 2 first month (mo) (±7 d)	Visit 3 second mo (±7 d)	Visit 4 third mo (±7 d)	Visit 5 sixth mo (±7 d)	Visits every 3 mo	v15 36 mo
	Washout (−3 weeks to −1 week)	Visit 1a (−1 week to day0)
Physical examination		+		+	+	+	+	+
Blood routine		+		+	+	+	+	+
Urine routine		+		+	+	+	+	+
Uric creatinine		+		+	+	+	+	+
Glycosylated haemoglobin		+				+	+	+
Serum uric acid		+		+	+	+	+	+
Creatinine, potassium, sodium, calcium, phosphorus, bicarbonate, bilirubin, albumin		+		+	+	+	+	+
Parathyroid hormone		+				+	+	+
Erythropoietin, folic acid, serum ferritin, transferrin		+				+	+	+
Serum lipid		+		+	+	+	+	+
24 hours urine output		+		+	+	+	+	+
Dialysis dose		+		+	+	+	+	+
Kt/V, renal creatinine clearance rate, peritoneal creatinine clearance rate		+		+	+	+	+	+
Peritoneal equilibrium test		+					every six mo	+
24 hours ultrafiltration		+		+	+	+	+	+
Pregnancy test (female)		+		+	+	+	+	+
ECG		+				+	+	+
Cardiac ultrasonography and vascular ultrasound		+					every 12mo	+

*Treatment in both groups and follow-up will last for another 3 years. In the first 3 months at the start of the study, visit intervals will be monthly. After that, visit intervals will be every 3 months until the end of study. Examinations will involve outpatient appointments in either outpatient clinics or private nephrology practices and will include: history and physical examination, measurement of systolic and diastolic arterial blood pressure, recording of the frequency, type, severity and duration of adverse events as well as laboratory tests including repeated blood counts.